Aim: To explore the physiological consequences of the ryanodine receptor (RyR2)-P2328S mutation associated with catecholaminergic polymorphic ventricular tachycardia (CPVT s/s hearts showed higher incidences of nsVTs before but mainly sVTs after introduction of isoproterenol with both regular stimuli and PES, particularly at higher pacing frequencies. Additionally, intrinsically beating RyR2 s/s showed extrasystolic events often followed by spontaneous sVT.
. Each ($565 kDa) RyR2 monomer is associated with a range of accessory, potentially regulatory, proteins. These include calmodulin (CaM), the 12.6 kDa protein FKBP12.6 (also known as calstabin 2), protein kinase A (PKA), protein phosphatase 1 and 2A (PP1 and PP2A), and calmodulin-dependent protein kinase II (CaMKII) bound to its cytoplasmic scaffold domain at the N-terminal region (Bers 2002) . It has been suggested that FKBP12.6 binding to RyR2 stabilizes the closed state of the channel during diastole and promotes the coupling of RyR2 subunits enabling channel opening during excitation contraction coupling (Yano et al. 2000 , 2005a , Bers 2002 .
The gene encoding RyR2s has been implicated in the autosomal dominant inherited condition, catecholaminergic polymorphic ventricular tachycardia (CPVT), which is associated with presentations of adrenergically (exercise)-induced bi-directional and polymorphic ventricular tachycardia (VT) potentially leading to sudden cardiac death (SCD) in the absence of structural cardiac disease (Laitinen et al. 2001 , Priori et al. 2001 , 2002 , Wehrens & Marks 2003 . It has been suggested that an increased release of SR Ca 2+ into the cytosol causes delayed diastolic afterdepolarizations (DADs) in the action potential leading to triggered activity in common with findings in digitalis-induced VT (Rosen & Danilo 1980 , Leenhardt et al. 1995 , Tunwell et al. 1996 , Priori et al. 2001 , Kummer et al. 2006 . Thus recent reports have similarly implicated alterations in SR calsequestrin in such pathology (Chopra et al. 2007) . Two groups first identified RyR2 mutations in CPVT patients; neither reported structural cardiac abnormalities or echocardiographic evidence of cardiac failure (Laitinen et al. 2001 , Priori et al. 2001 . The first reported four missense mutations of which S2246L, R2427S and N4104K were sporadic and R4497C was found in five clinically affected mutant carriers. The second group demonstrated three unrelated Finnish families carrying mutations in P2328S, Q4201R and V4653F. Seventeen members of the first of these families carried the P2328S mutation. Of these, 10 of the 12 studied showed exercise-induced VT. Two of these P2328S carriers were asymptomatic but showed abnormalities on clinical testing. The carriers within the family showed normal QTc intervals, and mortality rates as reflected in Kaplan-Meier analyses of 30-33% by the age of 35 years in common with the Q4201R and V4653F carriers.
Genetically modified murine hearts are increasingly used as models of human cardiac disease (London, 2001) . However, translation of results from isolated murine hearts to the in vivo clinical setting must consider differences between both (1) species as well as (2) the electrophysiological assessment protocols employed. Thus (1) despite similar anatomy and fibre organization, murine and human hearts are markedly different in basal heart rate, heart size and ion channel expression (Vaidya et al., 1999) . Although murine and human ventricular APs share a steep upstroke reflecting rapid Na + channel gating (Guo et al. 1999 ) and a strong influence of transient outward repolarizing K + current (I to ) on AP recovery, differences in repolarizing currents cause murine ventricular APs to overshoot and fall sharply in contrast to the pronounced plateau phase of the human ventricular AP (Danik et al. 2002) . (2) A significant proportion of the physiological assay techniques examined isolated perfused as opposed to in situ hearts for limited (h) rather than prolonged (years) intervals. Nonetheless, at the very least, murine hearts provide useful resemblances with human hearts the extent of which merits basic investigation. Thus, they have successfully been used to replicate arrhythmogenic properties associated with Brugada (BrS) and LQT3 syndromes (Stokoe 2007a,b; Thomas et al. 2007a,b) . Similarly, a CPVT-like arrrhythmogenesis has been observed under conditions of adrenaline and/or caffeine perfusion in a recent murine model with RyR2 modifications targeted instead at the C-terminal luminal sites implicated in store-overload-induced Ca 2+ release (SOICR) (Jiang et al. 2004 , Cerrone et al. 2005 . This article reports the generation of murine hearts containing P2328S mutations in the central region of the RyR2 gene close to the FKBP12.6 binding site, and represents the first time both heterozygotic (p/s) and homozygotic (s/s) transgenic mice are compared and studied. Previous studies in HEK293 cells had associated the P2328S variant with altered FKBP12.6 binding following PKA phosphorylation . This variant therefore directly complements genetically modified murine hearts with alterations targeted at the C-terminal luminal sites thought to be involved in SOICR (Jiang et al. 2004 , Cerrone et al. 2005 . The present experiments examined the physiological consequences of both p/s and s/s mutations not only through cytosolic Ca 2+ measurements in isolated cardiac myocytes but also electrophysiological recordings in Langendorffperfused hearts, and the extent to which the intact murine systems show arrhythmogenic properties. Our experiments thus clarified the physiological consequence of the P2328S (p/s) and (s/s) mutation, and defined the extent to which results from physiological studies demonstrate that this murine system resembled the human phenotype.
Material and methods

Generation of RyR2
P2328S knock-in mice
The targeting vector for homologous recombination consisted of a 5.89 kb genomic DNA fragment spanning a region from intron 44 to intron 47 of the RyR2 genomic sequence. The 5¢ and 3¢ flanks were amplified from 129Sv/Ev genomic DNA by PCR with PfuTurbo (Stratagene, Amsterdam, the Netherlands) using primers designed to the mouse genome reference sequence ENSMUSG00000021313. The codon change leading to the P2328S variant occurs in exon 45. The 5¢ flank was amplified using primers on either side on exon 45 to produce a 965-bp fragment. The forward primer contained an AvrII site which could be used to linearize the final targeting construct (5¢flankror: GTAAAGAAT-GAGACCTAGGATATAGTT; 5¢ flankrev: GCTTAG-CTAGCCTGAAAATACCTACA). The 3¢ flank was a 4925-bp PCR product amplified to continue the genomic homology from a NheI site at the 3¢ end of the 5¢ flank. Both forward and reverse primers contained NotI sites for cloning into the targeting construct. (3¢ flankfor: GCTAAGCGGCCGCAAAGAACACAGT TCAGAAACCTAT; 3¢flankrev: ATGGTAGCGGCC-GCTACCTAATATCACAAACACA). Both flanks were cloned into pCR-BluntII-Topo (Invitrogen, Paisley, UK) and sequenced. Clones whose exon sequence was 100% identical to that predicted by the database were chosen to form the targeting construct. Single base changes to intron sequence (compared to the mouse genome sequence, C57Bl/6) were accepted if they occurred in more than one clone. To introduce the required mutation into the 5¢ flank the Invitrogen GeneTailor site-directed mutagenesis system was used. The forward mutagenesis primer (GGTGAGGCTGCT CATCCGGAGAtCtGAGTGCTT) changes the coding sequence from proline (CCC) to serine (tCt) and introduces a novel BglII site for screening for introduction of the mutation. (reverse primer: TCTCCGGATGAGC AGCCTCACCACAACATTT). Plasmids which had been correctly mutagenized were identified by sequencing and digestion with BglII (pCR-RyR25¢P2328S).
To create the targeting construct, the 3¢ flank was cloned into the NotI site of pCR-RyR25¢P2328SDTA. To reduce non-homologous recombination in the ES cells the PGK promoter-driven Diptheria toxin-A chain gene (from pKO3¢/DT-Anew, a kind gift of Dr Michael Snaith) was introduced 3¢ of the 3¢ flank. The loxP flanked thymidine kinase/neomycin selection cassette (loxPtkneo) (from plasmid pNT4) was added between the two flanks to give the final targeting construct, pCRRyR25¢P2328SloxPtkneo3¢DTA (Fig. 1a) . The targeting construct was checked by sequencing and restriction digestion at each stage of its construction.
Two electroporations of the linearized targeting construct into 129Sv/Ev ES cells were performed from which 132 ES clones were picked. After PCR screening for correct homologous recombination of the 5¢ (Hotstar Taq: Qiagen, West Sussex, UK) and 3¢ flank (Long Range Taq: Fermentas, York, UK) only one clone was found to be positive. The primer positions for this screening are indicated in Figure 1a . The PCR products of each screen were cloned and sequenced to show that there had been no sequence rearrangements and that the only detectable sequence change was the desired introduction of the codon change. This was confirmed by BglII digestion. The ES clone was karyotyped to confirm it had the correct number of chromosomes (40).
To remove the loxPtkneo selection cassette this clone was electroporated with plasmid expressing Cre Recombinase (pPGKnlsCreSV40polyA, a kind gift from Dr Sam Aparicio) and selected in gancyclovir to promote the loss of the loxPtkneo selection cassette. Twelve colonies were picked and screened by PCR to check for loss of the selection cassette (Primers RyR2f: GGGGAGTTGGCTGCTGAGAA; RyR2r: CGGGCA-CACACTCACCACCAA). The PCR product was cloned and sequenced to confirm that it contained the expected RyR2 genomic sequence with 204 bp of vector, including a single loxP site, introduced into intron 45 at the NheI site at the end of the 5¢ flank. The karyotype of the new clone was reconfirmed and then this clone was injected into C57Bl/6 blastocysts to produce chimeras. Confirmed germline transmitting chimeras were mated to 129Sv/Ev females. The line was then maintained as a mixture of RyR2 p/s heterozygous matings or RyR2 s/s homozygous matings.
Reverse transcription PCR. Total RNA was isolated from mouse ventricle or skeletal muscle using the Qiagen RNeasy fibrous tissue mini kit. The RNA was quantified using a Nanodrop ND-1000 (NanoDrop Technologies, Inc., Wilmington, DE, USA, supplied by LabTech International, East Sussex, UK) and 0.5 lg of RNA was reverse transcribed using random primers and AMV Reverse Transcriptase (both from Promega, Southampton, UK) in the following reaction: RNA was incubated at 70°C for 10 min, then placed on ice and the following reagents added: 2 lL 0.1 m DTT, 4 lL 5· RT buffer, 1 lL 10 mm dNTPs, 1 lL lg
Random primers, 0.5 lL RNAguard (Pharmacia, Sandwich, UK), 10 U AMV RT in a total volume of 10 lL. The reaction mix was then incubated at 25°C for 10 min, 42°C for 60 min and 70°C for 15 min. Control reactions in which the RT enzyme was replaced with water were included to exclude amplification from genomic DNA. The resulting cDNA was then diluted to 50 mL and stored at )80°C. To set up the PCR reaction 2 lL of cDNA was added to 0.5 lL 10 mm RTRev, CCAGCATGAATCAAGTGCATTTC; mm b actin for, GTTACCAACTGGGACGACATGG, mm b actin rev, CCATACCCAAGAAGGAAGGCTG. The PCR products were digested by addition of BglII to the PCR mix and incubation at 37°C for 2 h. The digest was analysed by electrophoresis on a 2% agarose gel.
All mice used were originally supplied by Harlan (Oxon, UK) and were housed at room temperature and subjected to 12-h light/dark cycles. They were fed sterile rodent chow and had free access to water at all times. Mice used were wild-type (WT), heterozygote (RyR2 
Measurements of cell [Ca 2+ ]
Single-cell experiments used mouse ventricular myocytes isolated adapting an established enzymatic digestion as described previously (Harding et al. 1992) . Following killing, hearts were excised rapidly and cannulated before being connected to a Langendorff perfusion system. The heart was then perfused for 1.5 min at 3 mL min )1 with perfusion buffer containing (mm), 120 NaCl, 5 MgSO 4 , 5.4 KCl, 5 sodium pyruvate, 10 Hepes, 5 glucose, 20 taurine, 5 nitrilotriacetic acid (NTA; Sigma-Aldrich, Poole, UK), and 1-2 lm Ca 2+ , pH 7.0 at 37°C. Subsequently the heart was perfused for 25-28 min at 3 mL min )1 with digestion buffer containing (mm), 120 NaCl, 5 MgSO 4 , 5.4 KCl, 5 sodium pyruvate, 10 Hepes, 5 glucose, 20 taurine, to which was added collagenase type II (final concentration 1 mg mL )1 ; Worthington Biochemical, Lakewood, NJ, USA), hyaluronidase (final concentration 1 mg mL )1 ; Sigma-Aldrich) and 13 lm Ca 2+ and set at pH 6.8 at a temperature of 37°C. The pale and swollen heart was then removed and cut below the atria. The digested tissue was teased gently with fine forceps and the dissociated cells were transferred to a conical tube containing 12.5 mL digestion buffer with 50 mg bovine serum albumin (BSA) to inactivate digestion. The resulting myocytes were subject to further trituration using sterile plastic transfer pipettes, and allowed to sediment by gravity for 10 min.
The cell suspension was then centrifuged for 1.5 min at 200 rpm and the pellets re-suspended twice in wash buffer containing (mm): 119 NaCl, 4.2 KCl, 0.94 MgSO 4 , 1.2 KH 2 PO 4 , 20 Hepes, 11.5 glucose, 20 taurine and 1 mg mL )1 BSA, and bubbled with 95% O 2 + 5% CO 2 , pH 7.4, to remove all traces of NTA, collagenase and hyaluronidase. CaCl 2 was then cautiously re-introduced by stepwise additions of CaCl 2 to reach an approximate concentration of 1.25 mm by centrifuging the preparation at each Ca 2+ reloading stage to remove dead or swollen cells. During this process, myocytes were examined periodically under the microscope to confirm a good yield of rod-shaped myocytes (better than 60%) before continuing the experiments. Cells were then transferred into a conical tube (BD Biosciences, Oxford, UK) and incubated at room temperature. The isolated myocytes were then placed in a control Hepes-buffered Krebs-Henseleit (KH) solution in a Perspex chamber 10 · 4 · 6.25 mm (length · width · depth): the myocytes spontaneously attached to the glass cover slip (4 · 4 cm, grade 1 cover slip; (Merck, Herts, UK) forming the floor of the chamber. The myocytes were stimulated to contract using two in-built platinum field electrodes running the length of the chamber through which the periodic field stimulation was applied using a home-built squarewave stimulator (R. Montgomery, Imperial College, London, UK). This applied successive 40-60 V steps of 2.2 ms duration, immediately followed by a step of similar duration and amplitude but opposite polarity at a pacing frequency of 0. 
Whole heart electrophysiological experiments
The electrophysiological experiments on arrhythmogenesis at the whole heart level used a Langendorffperfused preparation adapted for the murine model (Papadatos et al. 2002 , Balasubramaniam et al. 2003 .
The contracting heart was stimulated with platinumstimulating electrodes applied to the epicardial surface, usually 15 min at 10 Hz, and was allowed to reach its physiological steady state. The heart was paced from its right ventricle at three times its threshold level (between 3 and 5 V) using square-wave stimuli of 2 ms duration (Grass S48 stimulator; Grass Telefactor (UK), Slough, UK). Monophasic action potentials (MAPs) were recorded from the epicardial basal surface of the left ventricle using a MAP electrode (Linton Instruments, Harvard Apparatus, Edenbridge, UK). Hearts were subject to two stimulation protocols. First, they were regularly paced at 6, 8, 10 and 12 Hz for periods of up to 30 min to assess for tendencies to spontaneous arrhythmogenesis. Secondly, programmed electrical stimulation (PES) of the heart was then carried out using a variation of an existing clinical technique (Saumarez & Grace 2000 . This applied stimulation sequences that each consisted of a drive train of pacing stimuli (S1) applied with a 200 ms cycle length with an extra stimulus (S2) inserted every eighth beat. The coupling interval (S1S2) was successively reduced by 1 ms with each cycle until the ventricular effective refractory period (VERP) was reached. The MAP signals were amplified, filtered (band-pass filter 30 Hz to 1 kHz; Gould-Nicolet Technologies, Ilford, Essex, UK) and digitized using an analog-to-digital converter (Model 1401plus; Cambridge Electronic Design, Cambridge, UK).
The MAP signals were analysed with Spike II software (Cambridge Electronic Design) and MAP traces were selected according to previously documented criteria requiring stable baselines with rapid upstrokes and consistent amplitudes. The action potential durations (APD) at 30, 50, 70 and 90% repolarization (APD 30, APD 50 , APD 70 and APD 90 ) were fully identified and tabulated in Excel (Microsoft, Redmond, WA, USA). Results were all expressed as mean AE SEM comparing different groups of experimental animals using anova (spss software).
Isoproterenol was dissolved initially in distilled water to make a stock of 1 mm and the final drug concentration was achieved by dilution with the control KH buffer. The stocks were stored at )20°C and made fresh on the day of each experiment. These agents were obtained from Sigma-Aldrich.
Results
RyR2
P2328S mice
The three injections of embryonic stem cells into C57B/ 6 blastocysts resulted in a total of eight male chimeras. Each of these males was mated with Ca 57Bl/6 and a 129Sv/Ev female. Three of the chimeras showed germ line transmission of the knock-in allele, two produced no litters and two produced litters but did not show germ line transmission. Genotyping of pups was performed using primers RyR2f and RyR2r (Fig. 1a) . These span the vector sequence left in intron 46. A second PCR can be used to confirm the presence of the RyR2 P2328S allele. The reverse primer binds to vector sequence left in intron 45 and the primers span the introduced mutation to produce a 740-bp product which can be cut by BglII to produce two, 524 and 216 bp, products (Fig. 1b) To check that both alleles produced mRNA, RT-PCR was performed on total RNA isolated from mouse ventricle tissue. Figure 1c shows the results of RT-PCR after the product had been digested by BglII and the digest run on a 2% agarose gel. For each genotype the RT-PCR reaction was run in triplicate. RNA from WT mice produced a single product at 694 bp. RNA from the heterozygous RyR2 p/s mice produced three products, uncut WT allele and digested RyR2 P2328S allele.
RNA from the homozygous RyR2 s/s mice produced only two products (438 and 256 bp) showing that the RT-PCR product is derived from the RyR2 P2328S allele only. The b-actin gene was amplified in all samples as a positive control. PCR reactions using the )RT cDNA were also included as negative controls. No amplification was seen in these reactions from either the RyR2 or b-actin primers (data not shown). To show that the RyR2 primers were not amplifying from RyR1-derived cDNA, skeletal muscle-derived cDNA was used as a template. No amplification from the RyR2 primers was seen in these reactions, but the b-actin primers were able to amplify the expected product from the same samples (data not shown).
The presence of the P2328S allele alters Ca 2+ homeostasis Differences in cellular Ca 2+ homeostasis that might relate to the presence of the P2328S allele were first investigated through changes in the amplitude and pattern of Ca 2+ transients in response to regular stimulation (0.5 Hz) in isolated Fluo-3-AM loaded WT (Fig. 2a,b) , RyR2 p/s (Fig. 2c,d) and RyR2 s/s (Fig.   2e ,f) myocytes. These were studied in KH buffer in both the absence and presence of isoproterenol at a concentration (100 mm) at which it would be possible to assess the extent to which the RyR2 p/s or RyR2 s/s mutation might either increase or decrease the incidence of ectopic or subsidiary Ca 2+ events. In all three groups, the traces showed stable baseline F/F 0 and reproducible responses to regular stimulation with minimal evidence of fluorophor bleaching over the sampling periods. Thus the average values of the diastolic baseline F/F 0 were statistically indistinguishable (P >> 5%) between all three groups whether in the presence and absence of isoproterenol. Similar stability conditions applied to the corresponding peak F/F 0 amplitudes. We further quantified the characteristics of such peak F/F 0 (Table 1) obtained from Ca 2+ transients of the kind illustrated in Figure 2 . In the absence of isoproterenol, Ca 2+ signals observed immediately after the commencement of stimulation in WT (Fig. 2a) and RyR2 p/s myocytes (Fig. 2c) consisted of a series of responses each directly following the individual stimuli. WT (Fig. 2a) and RyR2 p/s myocytes (Fig. 2c) similarly did not show either subsidiary events during the recovery time courses of the evoked transients or spontaneous ectopic peaks in the intervals between these regular responses to the imposed stimuli. In contrast, the RyR2 s/s myocytes showed an irregular pattern of responses that included subsidiary events (4.65 AE 1.46 events counted over a standard sampling period of 50 s; n = 36 cells, three mice) (Fig. 2e) . After the addition of isoproterenol, WT myocytes showed both ectopic peaks (8.00 AE 2.99; n = 6 cells, two mice) and subsidiary events (9.00 AE 1.34, n = 6 cells, two mice) (Fig. 2b) (Fig. 3a,c,e) . Addition of isoproterenol then similarly resulted in the appearance of both ectopic peaks and subsidiary events in WT (Fig. 3b) and their continued absence in RyR2 p/s myocytes (Fig. 3d) .
Such results agreed with the findings made immediately following the onset of stimulation (Fig. 2) despite the now reduced peak F/F 0 values likely reflecting progressive SR Ca 2+ depletion by such prolonged stimulation.
RyR2
s/s myocytes showed irregular patterns of release events (Fig. 3f ). These were further studied (Fig. 4) under conditions of exposure to 0 (n = 7), 20 (n = 4), 50 (n = 4) and 100 nm (n = 5) isoproterenol respectively: this gave progressive (and significant) reductions in peak F/F 0 from 4.045 AE 1.021 to 3.846 AE 0.068 (n = 5), 1.63 AE 0.0048 (n = 5) and 1.470 AE 0.058 (n = 5; P = 0.03 on independent weighted analysis), in which a reduction in the frequency of subsidiary peaks from 16.33 AE 2.08 to 6.57 AE 1.72 and 5.8 AE 4.82, following a series of 22 stimulations in 20 and 50 nm isoproterenol, respectively, was replaced by the irregular pattern of release events at 100 nm isoproterenol (Fig. 4d) (Fig. 5) . The arrows highlight the path taken by the Ca 2+ wave, starting from the upper end of the cell and moving along its length. Similar results were observed in n = 5 cells.
Action potentials from hearts containing the P2328S allele during regular pacing
Experiments on isolated Langendorff-perfused whole hearts compared electrophysiological properties of WT, RyR2 p/s and RyR2 s/s hearts, exploring for arrhythmogenic tendency both before and following addition of 100 nm isoproterenol in each heart. Mice were aged between 3 and 6 months (WT: one female, two males; RyR2 p/s : four females, four males; and RyR2 s/s : one female, six males). The experiments used both regular pacing and PES procedures, which imposed an S2 extra stimulus following eight-beat (S1) conditioning , homozygote. Symbols indicate values subject to one-way anova of findings obtained between designated groups, or in each group before and after introduction of isoproterenol with the following results: P = ns, *P < 0.05, **P < 0.01, ***P < 0.001. sequences at S1S2 intervals progressively shortened with each stimulus cycle. Experiments used pacing (S1) frequencies of 6, 8, 10 and 12 Hz respectively. WT, RyR2 p/s and RyR2 s/s hearts paced at 10 Hz showed statistically indistinguishable VERPs of 63 AE 11.2 (n = 3), 56.3 AE 8.4 (n = 3) and 66.5 AE 18.5 ms (n = 3 hearts) respectively.
The experiments first examined MAP waveforms in hearts regularly paced at 10 Hz for at least 30 min in KH buffer before and after addition of isoproterenol. They assessed for the presence or absence of changes in APD of the kind reported for LQTS mice models on recent occasions (Head et al., 2005; Stokoe et al., 2007a,b; Thomas et al., 2007a,b) . APD values measured at 30, 50, 70 and 90% recovery (APD 30, 50, 70, 90 ) from regularly paced WT (n = 3 hearts), RyR2 p/s (n = 7 hearts) and RyR2 s/s (n = 7 hearts) before and 20 min after addition of isoproterenol indicated uniform MAPs (Fig. 6ai ,ii, bi,ii and ci,ii respectively), with no significant differences in all these APD durations between WT (Fig. 6aiii) , RyR2 p/s (Fig. 6biii) and RyR2 s/s hearts (Fig. 6ciii) . Such findings parallel reports on a previously described R4496C mutant where QT intervals, of WT and the mutant mice did not present significant differences whether before or after adrenergic stimulation (Cerrone et al. 2005) . These data therefore parallel findings that CPVT carriers of the RyR2-P2328S mutation (Paavola et al. 2007) showed increases in endocardial MAP durations considerably smaller than the clinical QTc prolongations thought to account for the LQTS phenotype (Keating & Sanguinetti, 2001; Scoote & Williams, 2002; Laurita & Katra, 2005; .
Arrhythmic properties of hearts containing the P2328S allele during regular pacing and programmed electrical stimulation at varying frequencies
The presence or absence of an arrhythmogenic phenotype was then investigated in the WT, RyR2 p/s and RyR2 s/s hearts subject to both regular pacing and PES.
VT was identified as a series of regular electrical deflections recurring at high frequencies independent of any pacing spikes that were present. Arrhythmias lasting >30 s were defined as being sustained (sVT) and those lasting <30 s as being non-sustained (nsVT). On these criteria: (1) regularly paced WT hearts showed no arrhythmic incidents at all frequencies (6, 8, 10 and 12 Hz) explored whether isoproterenol was present (n = 3) or absent (n = 4 hearts) (data not shown). (2) The RyR2 p/s hearts showed relatively few arrhythmogenic phenomena, when regularly paced, in the absence of isoproterenol. Thus, of seven hearts, only one then showed an episode of sVT at a pacing rate of 12 Hz. However, addition of isoproterenol (100 nm) enhanced arrhythmic tendency with 1, 1 and 0 episodes of nsVT at pacing frequencies of 6, 8 and 10 Hz and 0, 1, 0 and 1 episodes of sVT at a pacing frequency of 6, 8, 10 and 12 Hz respectively (n = 5 hearts). (3) RyR2 s/s hearts showed noticeably greater arrhythmic tendencies even prior to addition of isoproterenol (Fig. 7) . Two hearts then showed episodes of nsVT at 8 and 10 Hz (Fig. 7b) , and two further hearts showed episodes of sVT at 10 Hz (n = 11 hearts). (4) Addition of isoproterenol increased this arrhythmic tendency. Thus, its introduction resulted in (n = 5 hearts) 2, 1, 0 and 0 episodes of sVT at pacing frequencies of 6, 8, 10 and 12 Hz respectively. Finally, spontaneous after-depolarizations, previously implicated in the triggering of arrhythmias, were observed in hearts paced at both 8 and 10 Hz (n = 2) (Fig. 7c) . The subsequent electrophysiological experiments explored for arrhythmogenic substrate as reflected in initiation of VT by extrasystolic (S2) stimulations applied during PES procedures (Fig. 8) . This gave results that correlated well with the pacing studies. They demonstrated that (5) WT hearts were not arrhythmogenic at all pacing frequencies, whether before (n = 4, Fig. 8a ) or after (n = 3, Fig. 8b ) introduction of isoproterenol. In contrast, (6) both RyR2 p/s and RyR2 s/s hearts showed an arrhythmogenicity exacerbated by isoproterenol. Thus, five of seven RyR2 p/s hearts (Fig. 8c) showed nsVT at all applied pacing frequencies. Isoproterenol (100 nm) increased this incidence in four of five hearts. The RyR2 s/s hearts showed not only higher incidence of nsVT, but also an occurrence of sVT (n = 11 hearts, Fig. 8e ). Addition of 100 nm isoproterenol resulted in full sVT (n = 5) (Fig. 8f) . Taken together, these results suggest that the RyR2-P2328S mutation results in increased tendencies to nsVT as well as sVT in mice. This is common with features shown by CPVT patients with RyR2 mutations (Swan et al. 1999 , Laitinen et al. 2001 , Priori et al. 2001 , 2002 .
RyR2 s/s hearts additionally show arrhythmic behaviour during intrinsic activity
Spontaneous arrhythmogenic phenomena were only observed in intrinsically paced RyR2 s/s and not in WT (n = 3) or RyR2 p/s (n = 7). Six of 11 RyR2 s/s hearts showed early after depolarizations (EADs) that intercepted the recovery phase of their preceding action potentials (Fig. 9a) , and 11 of 11 showed coupled beats consisting of pairs of full action potentials (Fig. 9b) .
There was one example of nsVT following the coupled beats. When stimulation was ceased and re-introduced at a pacing rate of 10 Hz, it resulted in an episode of ventricular fibrillation (Fig. 9c) . These findings are consistent with reports in which CPVT patients exhibited episodes of polymorphic VT leading to SCD while asleep or at rest (Allouis et al. 2005 , d'Amati et al. 2005 , Postma et al. 2005 .
Discussion
Catecholaminergic polymorphic ventricular tachycardia (CPVT) associated with SCD (Wehrens & Marks 2003 , Francis et al. 2005 , George et al. 2007 , has been linked to mutations in the gene encoding the ryanodine receptor (RyR2)-sarcoplasmic reticular Ca 2+ release channel (Swan et al. 1999 , Priori et al. 2001 . The mutations concerned are primarily clustered in three regions of the gene namely, the N-terminal region (176-433), central domain (2246-2504) and the C-terminal region (4104-4653) (Wehrens & Marks 2003) . In contrast to murine models directed to the C and N-terminal regions, there have been no such models involving the important central region (Cerrone et al. 2005 , Kannankeril et al. 2006 . This study reports the generation of mice with a knock-in mutation in the central domain of the RYR2 gene (P2328S). The variant was first identified, in common with carriers for the Q4201R and V4653F in three unrelated Finnish families. The P2328S mutation is located in the large central cytoplasmic domain of RyR2, near the binding site of the regulatory protein FKBP12.6 (George et al. 2007) ; the Q4201R and V4653F mutations occur in the carboxy-terminal region of the receptor associated with the pore region (Tunwell et al. 1996) . All the human carriers showed mortality rates of %33% between the ages of 10 and 35 years and threshold heart rates of $130 beats min )1 for the triggering of ventricular arrhythmogenesis during exercise despite an absence of structural abnormalities or heart failure (Laitinen et al. 2001) . Recent clinical studies of carriers for the P2328S, as well as the Q4201R and V4653F, mutations reported runs of polymorphic tachycardia during exercise with a mean age of onset of symptoms of 34 AE 16 years. Furthermore, endocardial MAP recordings at the right ventricular septum from patients with one of the three RyR2 mutations showed delayed afterdepolarizations (DADs) in three of 15 CPVT patients. These occasionally coincided with premature ventricular complexes both before and during adrenaline infusion that were never observed in control subjects (Paavola et al. 2007 ). There has been extensive discussion about the association between mutations in the RyR2, including that of P2328S, and the CPVT phenotypes, particularly concerning possible roles of FKBP12.6-RyR2 binding (Brillantes et al., 1994; Masumiya et al. 2003 , Zissimopoulos & Lai 2005 and 12 Hz, respectively, and one heart showed sVT both at 10 and 12 Hz. The RyR2 s/s hearts showed 3, 3, 3, and 5 episodes of nsVT and 0, 1, 3 and 1 episodes of sVT at pacing rates of 6, 8, 10 and 12 Hz respectively (n = 11 hearts). Addition of 100 nm isoproterenol (n = 5) resulted in a high incidence (2, 3, 3 and 4 episodes) of sVT. In the example shown, the S2 extra-stimuli initiated an episode of non-sustained VT lasting for less that 30 s in KB buffer alone (e). Sustained VT lasting for more than 30 s was often observed following addition of 100 nm isoproterenol in the same heart during PES at 10 Hz (f). Scale bar 200 ms.
V4653F) mutations suggested a gain-of-function defect with leaky Ca 2+ release channels showing significant rightward shift in half-maximal inhibitory Mg 2+ concentration and decreased FKBP12.6 binding , Paavola et al. 2007 . However, other studies have reported that mutations in the RyR2 central region variously showed increased (N2386I and Y2392C) and decreased (R2427S, S2246L and P2328S) FKBP12.6 binding affinity (Tiso et al. 2002 and Wehrens et al. 2003 respectively) , although a decreased affinity with C-terminal mutations (Q4201R, R4496C and V4653F) . S2808D-myotubes did not show spontaneous Ca 2+ oscillations at any concentration of FKBP12.6 (Goonasekera et al., 2005) . Fluorescence resonance energy transfer investigations of the functional impact of C-terminal and central domain RyR2 mutations suggested effects on RyR2 channel activity independent of FKBP12.6 binding and PKA phosphorylation and reviewed in George et al. 2003 , Jiang et al. 2004 , Liu et al. 2006 ryanodine binding (see also Jiang et al. 2005) . Such findings were corroborated using the first RyR2-R4496C (+/)) knock-in mouse model equivalent to the R4497C mutation identified in CPVT patients. Five of 14 such mice showed either nsVT or sVT only with exercise stress testing followed by adrenaline administration. Four of eight of a second group developed arrhythmias following adrenaline and caffeine administration, as did four of five pre-treated with K201 (Cerrone et al. 2005) . Recent optical mapping studies further characterized these arrhythmogenic characteristics (Cerrone et al. 2007 ). Subsequent analyses demonstrated that pacing protocols of increasing frequencies induced DADs in RyR2-R4496C (+/)) cardiomyocytes but not in the WT. Superfusion with isoproterenol induced both DADs and triggered activity in the RyR2-R4496C (+/)) but not in the WT. Finally, the heterozygote showed slightly increased RyR2-FKBP12.6 interaction compared with WT that was unchanged in the presence or absence of caffeine and adrenaline (Liu et al. 2006) . Our data provide complementary mouse models using the P2328S mutation, at a central site remote from the luminal C-terminal, R4496C site. We have for the first time compared all three genotypes (WT, RyR2 were more marked at higher pacing frequencies and in the RyR2 s/s hearts. The latter showed the greatest arrhythmogenic tendency as well as extrasystolic events often followed by spontaneous sustained VT even during intrinsic beating. In addition to establishing an arrhythmogenic phenotype, and associating this with altered Ca 2+ homeostasis, these data therefore associated a physiological CPVT phenotype with the clinically described P2328S mutation, in the cytoplasmic central region of the RyR2.
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